Ever wondered which patients get GU adverse events after prostate SBRT? Some pointers here https://t.co/dQcqRXTN4O
6
33
76
Replies
Congratulations to Dr Ragu Ratnakumaran for all his hard work deciphering the mountain of data from PACE-B
1
1
15
@alison_tree @nickva1 @EmmaHall71 @ICR_CTSU @DrAndrewLoblaw Thanks Absolutely, having baseline IPSS is key and trying to optimize LUTS prior to RT is a must regardless of the selected frx. We are currently looking into other predictive radiologic biomarkers that may further enhance our prediction of outcome in terms of gu tx.
1
0
1
@Adham_Hijab @nickva1 @EmmaHall71 @ICR_CTSU @DrAndrewLoblaw Sounds interesting @Adham_Hijab , I look forward to hearing your results.
0
0
1
@alison_tree @nickva1 @EmmaHall71 @ICR_CTSU @DrAndrewLoblaw Thank you. Is this cumulative incidence or prevalence at 2 years?
1
0
0
@tommyrochmn @nickva1 @EmmaHall71 @ICR_CTSU @DrAndrewLoblaw Good question. This figure is for incidence at 2 years. Cumulative to 2 years is more stark (23% G2+ vs 51% for IPSS>11 (suppl Figure 5)
0
0
1
0
0
0
@alison_tree @nickva1 @EmmaHall71 @ICR_CTSU @DrAndrewLoblaw Surprising results fiducials vs. no fiducials in the linac group. @DrAndrewLoblaw
@marslain
0
0
0
@alison_tree @nickva1 @EmmaHall71 @ICR_CTSU @DrAndrewLoblaw this is incredible work! perhaps we can collaborate more as our @MoffittNews group firmly believes the same - namely that improving baseline LUTS prior to RT results in improved urinary function after RT! that’s what #pae is great for! https://t.co/veBpY30rWv
1
2
3
ANNOUNCING: The next #ISRSWebinar “Single Fraction SBRT for Oligometastases” 🗓️ Thurs, November 10, 2025 | 6pm CET 🥼Rob Olson MD, FRCPC, MSc Radiation Oncologist | Executive Medical Director, BC Cancer – Prince George Professor | Division Head of Radiation Oncology, UBC Dr.
0
3
5
A flowchart that outlines the diagnostic and treatment pathway for Vitamin B12 deficiency. https://t.co/B6I3dWCzsC
0
15
61
Provocative study of ChemoIO for Omission of RT for stage III NSCLC(!) Evolution phase II study from Japan. In pts with PD-L1 TPS >50%, pembro+chemo induction and pembro maintenance had 2 yr PFS 67%, which arguably is comparable to PACIFIC. Is any local tx needed? #radonc
0
6
25